Lithium has been used as a psychiatric medication and mood stabilizer for thousands of years, beginning with the ancient Greeks’ use of lithium-rich spring waters. High-dose lithium is prescribed for bipolar disorder and severe depression, usually in the form of lithium carbonate (100-2000mg, 18.8% Li → 20-375mg Li).
Recently, the [//en.wikipedia.org/wiki/Neuroprotection neurotropic and neuroprotective] properties of low-dose lithium (25-120 mg lithium orotate, 4.3% Li → 1-5mg Li) in both acute (e.g. stroke) and chronic (e.g. depression, dementia) contexts have been evaluated. Studies have also correlated higher levels of natural lithium in the water supply with reduced rates of suicide and violent crime in [//www.ncbi.nlm.nih.gov/pubmed/23312137 Texas], [//bjp.rcpsych.org/content/194/5/464.full Japan], [//www.ncbi.nlm.nih.gov/pubmed/24072668 Greece], and [//www.ij-healthgeographics.com/content/11/1/19 Austria].
Low-dose lithium has no side effects, and these results have led some researchers to suggest supplementing the water supply in low-lithium regions. It has even been proposed that [//dx.doi.org/10.1080/07315724.2002.10719188 lithium is an essential nutrient] with a Recommended Dietary Allowance (RDA) of 1 mg per day.
[//en.wikipedia.org/wiki/Lithium Wikipedia: Lithium]
[//en.wikipedia.org/wiki/Lithium_%28medication%29 Wikipedia: Lithium (medication)]
[//en.wikipedia.org/wiki/Lithia_water Wikipedia: Lithia Water]
[//en.wikipedia.org/wiki/Lithia_%28water_brand%29 Wikipedia: Lithia (water brand)]
molecule | molecular weight |
---|---|
lithium (Li⁺) | 6.94 g/mol |
carbonate (CO₃²⁻) | 60.0 g/mol |
orotate | 155.1 g/mol |
Popular Press ————-
[//www.nytimes.com/2014/09/14/opinion/sunday/should-we-all-take-a-bit-of-lithium.html New York Times: Should We All Take a Bit of Lithium?]
[//bigthink.com/dangerous-ideas/1-drug-our-drinking-water Big Think: Drug Our Drinking Water (with Lithium)]
[//www.psychologytoday.com/blog/evolutionary-psychiatry/201201/could-you-have-lithium-deficiency Psychology Today: Could You Have a Lithium Deficiency?]
[//dx.doi.org/10.1016/S0140-6736(00)02793-8
Lithium-induced
increase
in
human
brain
grey
matter.]
Moore, G. J., Bebchuk, J. M., Wilds, I. B., Chen, G., & Menji, H. K. (2000).
The Lancet, 356(9237), 1241–1242.
[//dx.doi.org/10.1016/S0006-3223(00)00252-3
Lithium
increases
N-acetyl-aspartate
in
the
human
brain:
in
vivo
evidence
in
support
of
bcl-2’s
neurotrophic
effects?]
Moore, G. J., Bebchuk, J. M., Hasanat, K., Chen, G., Seraji-Bozorgzad, N., Wilds, I. B., … Manji, H. K. (2000).
Biological Psychiatry, 48(1), 1–8.
[//dx.doi.org/10.1016/j.jad.2004.01.002
Mood
stabilizers:
protecting
the
mood...protecting
the
brain.]
Brunello, N. (2004).
Journal of Affective Disorders, 79 Suppl 1, S15–20.
[//dx.doi.org/10.1177/2045125312471963
Lithium:
the
pharmacodynamic
actions
of
the
amazing
ion.]
Brown, K. M.; Tracy, D. K. (2013)
Ther. Adv. Psychopharmacol. 2013, 3, 163–176
[//dx.doi.org/10.1080/07315724.2002.10719188
Lithium:
Occurrence,
Dietary
Intakes,
Nutritional
Essentiality.]
Schrauzer, G. N.
J. Am. Coll. Nutr. 2002, 21, 14–21
[//www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2804881&tool=pmcentrez&rendertype=abstract
The
neurotrophic
and
neuroprotective
effects
of
psychotropic
agents.]
Hunsberger, J., Austin, D. R., Henter, I. D., & Chen, G. (2009).
Dialogues in Clinical Neuroscience, 11(3), 333–48.
[//www.ncbi.nlm.nih.gov/pubmed/10509176
Lithium
at
50:
have
the
neuroprotective
effects
of
this
unique
cation
been
overlooked?]
Manji, H. K., Moore, G. J., & Chen, G. (1999).
Biological Psychiatry, 46(7), 929–40.
[//dx.doi.org/10.1016/S0006-3223(00)00979-3
Clinical
and
preclinical
evidence
for
the
neurotrophic
effects
of
mood
stabilizers:
implications
for
the
pathophysiology
and
treatment
of
manic–depressive
illness.]
Manji, H. K., Moore, G. J., & Chen, G. (2000).
Biological Psychiatry, 48(8), 740–754.
[//europepmc.org/abstract/MED/10826666
Lithium
up-regulates
the
cytoprotective
protein
Bcl-2
in
the
CNS
in
vivo:
a
role
for
neurotrophic
and
neuroprotective
effects
in
manic
depressive
illness.]
Manji, H. K., Moore, G. J., & Chen, G. (2000).
The Journal of Clinical Psychiatry, 61 Suppl 9(suppl 9), 82–96.
[//dx.doi.org/10.1016/S0006-3223(03)00117-3
Enhancing
neuronal
plasticity
and
cellular
resilience
to
develop
novel,
improved
therapeutics
for
Difficult-to-Treat
depression.]
Manji, H. K., Quiroz, J. a, Sporn, J., Payne, J. L., Denicoff, K., A. Gray, N., … Charney, D. S. (2003).
Biological Psychiatry, 53(8), 707–742.
[//altcancerweb.com/bipolar/lithium/overview-mechanism-action-lithium-2000.pdf
Overview
of
the
mechanism
of
action
of
lithium
in
the
brain:
fifty-year
update.]
Lenox, R., & Hahn, C. (2000).
Journal of Clinical Psychiatry, 6140(suppl 9).
[//www.ncbi.nlm.nih.gov/pubmed/10826659
Efficacy
of
lithium
in
mania
and
maintenance
therapy
of
bipolar
disorder.]
Bowden, C. L. (2000).
The Journal of Clinical Psychiatry, 61 Suppl 9, 35–40.
[//dx.doi.org/10.1124/pr.111.005512
Therapeutic
potential
of
mood
stabilizers
lithium
and
valproic
acid:
beyond
bipolar
disorder.]
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013).
Pharmacological Reviews, 65(1), 105–42.
[//www.ncbi.nlm.nih.gov/pubmed/10826662
Lithium
in
unipolar
depression
and
the
prevention
of
suicide.]
Coppen, A. (2000).
The Journal of Clinical Psychiatry, 61 Suppl 9(suppl 9), 52–6.
[//www.ncbi.nlm.nih.gov/pubmed/10826665
Optimizing
lithium
treatment.]
Dunner, D. L. (2000).
The Journal of Clinical Psychiatry, 61 Suppl 9(suppl 9), 76–81.
[//www.ncbi.nlm.nih.gov/pubmed/10826660
In
vivo
imaging
of
the
pharmacodynamics
and
pharmacokinetics
of
lithium.]
Kilts, C. D. (2000).
The Journal of Clinical Psychiatry, 61 Suppl 9(suppl 9), 41–6.
[//scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Introduction:+Fifty+Years+of+Lithium+Use+in+the+Treatment+of+Bipolar+Disorder#2
Introduction-Fifty
years
of
lithium
use
in
the
treatment
of
bipolar
disorder.]
Nemeroff, C. (2000).
Journal of Clinical Psychiatry, 61(suppl 9).
[//europepmc.org/abstract/MED/10826656
The
psychopharmacologic
specificity
of
the
lithium
ion:
origins
and
trajectory.]
Soares, J. C., & Gershon, S. (2000).
The Journal of Clinical Psychiatry, 61 Suppl 9(suppl 9), 16–22.
[//www.ncbi.nlm.nih.gov/pubmed/10826667
Reduced
suicide
risk
during
lithium
maintenance
treatment.]
Tondo, L., & Baldessarini, R. J. (2000).
The Journal of Clinical Psychiatry, 61 Suppl 9(suppl 9), 97–104.
[//dx.doi.org/10.1038/aps.2011.140
Beneficial
effects
of
mood
stabilizers
lithium,
valproate
and
lamotrigine
in
experimental
stroke
models.]
Wang, Z., Fessler, E. B., & Chuang, D.-M. (2011).
Acta Pharmacologica Sinica, 32(12), 1433–45.
[//dx.doi.org/10.1016/j.cnr.2004.09.006
Neurotrophic
signaling
cascades
are
major
long-term
targets
for
lithium:
clinical
implications.]
Yuan, P., Gould, T. D., Gray, N. a., Bachmann, R. F., Schloesser, R. J., Lan, M. J. K., … Manji, H. K. (2004).
Clinical Neuroscience Research, 4(3-4), 137–153.
MATHJAX_NODOLLAR